Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDT Stock Forecast 2026-2027
$96.95
Current Price
$124.35B
Market Cap
Buy 16
Hold 13
Sell 0
Wall St Analyst Ratings
Distance to MDT Price Targets
+28.9%
To High Target of $125.00
+15.5%
To Median Target of $112.00
+0.3%
To Low Target of $97.20
MDT Price Momentum
-3.3%
1 Week Change
-2.9%
1 Month Change
+18.5%
1 Year Change
+0.9%
Year-to-Date Change
-8.8%
From 52W High of $106.33
+21.9%
From 52W Low of $79.55
📊 TOP ANALYST CALLS
Did MDT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Medtronic is one of their latest high-conviction picks.
Latest MDT Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, MDT has a bullish consensus with a median price target of $112.00 (ranging from $97.20 to $125.00). The overall analyst rating is Buy (7.9/10). Currently trading at $96.95, the median forecast implies a 15.5% upside. This outlook is supported by 16 Buy, 13 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joshua Jennings at Cowen & Co., projecting a 28.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDT Analyst Ratings
16
Buy
13
Hold
0
Sell
MDT Price Target Range
Low
$97.20
Average
$112.00
High
$125.00
Current: $96.95
Latest MDT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Bernstein | Lee Hambright | Outperform | Maintains | $112.00 |
| Jan 8, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $116.00 |
| Jan 6, 2026 | William Blair | Brandon Vazquez | Outperform | Upgrade | $N/A |
| Dec 18, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $107.00 |
| Nov 20, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $110.00 |
| Nov 20, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $111.00 |
| Nov 19, 2025 | Goldman Sachs | David Roman | Neutral | Upgrade | $111.00 |
| Nov 19, 2025 | Morgan Stanley | Cecilia Furlong | Overweight | Maintains | $117.00 |
| Nov 19, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $114.00 |
| Nov 19, 2025 | Baird | David Rescott | Neutral | Maintains | $109.00 |
| Nov 19, 2025 | UBS | Danielle Antalffy | Neutral | Maintains | $102.00 |
| Nov 19, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $118.00 |
| Nov 13, 2025 | JP Morgan | Robbie Marcus | Neutral | Maintains | $100.00 |
| Oct 15, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $103.00 |
| Oct 9, 2025 | Stifel | Rick Wise | Hold | Maintains | $105.00 |
| Oct 7, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $112.00 |
| Aug 26, 2025 | Argus Research | David Toung | Buy | Maintains | $115.00 |
| Aug 21, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $101.00 |
| Aug 21, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $96.00 |
| Aug 20, 2025 | Baird | David Rescott | Neutral | Maintains | $96.00 |
Medtronic plc (MDT) Competitors
The following stocks are similar to Medtronic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medtronic plc (MDT) Financial Data
Medtronic plc has a market capitalization of $124.35B with a P/E ratio of 26.1x. The company generates $34.76B in trailing twelve-month revenue with a 13.7% profit margin.
Revenue growth is +6.6% quarter-over-quarter, while maintaining an operating margin of +20.3% and return on equity of +9.8%.
Valuation Metrics
Market Cap
$124.35B
Enterprise Value
$146.01B
P/E Ratio
26.1x
PEG Ratio
3.2x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+6.6%
Gross Margin
+65.8%
Operating Margin
+20.3%
Net Margin
+13.7%
EPS Growth
+8.2%
Financial Health
Cash/Price Ratio
+6.7%
Current Ratio
2.4x
Debt/Equity
59.6x
ROE
+9.8%
ROA
+4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Medtronic plc (MDT) Business Model
About Medtronic plc
What They Do
Develops and sells innovative medical devices.
Business Model
Medtronic generates revenue by designing, manufacturing, and selling a diverse range of medical devices and therapies, focusing on areas such as cardiovascular treatment, diabetes management, and neurosurgery. The company's extensive product portfolio allows it to cater to various medical procedures, ensuring a steady demand for its innovative solutions.
Additional Information
Founded in 1949 and headquartered in Dublin, Ireland, Medtronic is a prominent player in the healthcare technology sector. The company's continuous investment in research and development enables it to set industry standards and enhance patient care globally.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
95,000
CEO
Mr. Geoffrey Straub Martha
Country
Ireland
IPO Year
1981
Website
www.medtronic.comMedtronic plc (MDT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?
ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.
Jan 09, 2026
By Indrajit Bandyopadhyay
Analyst Blog
MDT or ESLOY: Which Is the Better Value Stock Right Now?
MDT vs. ESLOY: Which Stock Is the Better Value Option?
Jan 08, 2026
By Zacks Equity Research
Tale of the Tape
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
Jan 05, 2026
By Nalak Das
Analyst Blog
Latest News
Quick Summary
Vertex and Medtronic are expected to experience strong momentum this year, while Pfizer faces challenges. Both Vertex and Medtronic have attractive prospects moving forward.
Why It Matters
Vertex and Medtronic's strong momentum suggests potential growth, while Pfizer's challenges may hinder its performance, impacting investment decisions and portfolio strategies.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Products sector may consider Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY) for potential value opportunities.
Why It Matters
The comparison of Medtronic and EssilorLuxottica highlights potential value opportunities in the Medical - Products sector, influencing investment decisions based on performance and valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Medtronic plc (NYSE: MDT) will participate in the 44th annual J.P. Morgan healthcare conference on January 12, 2026.
Why It Matters
Medtronic's participation in a major healthcare conference could signal upcoming strategic insights or product announcements, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
William Blair upgraded Medtronic Plc (NYSE: MDT) on Tuesday, attributing the upgrade to several new product launches that are gaining traction.
Why It Matters
William Blair's upgrade of Medtronic indicates confidence in the company's growth potential due to new product launches, potentially boosting stock performance and investor interest.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
LLY, MDT, ISRG, REGN, and JNJ are five defensive medical stocks leveraging AI for growth and innovation through 2026.
Why It Matters
These stocks may offer stability and growth potential, leveraging AI for advancements, which can lead to increased revenues and market confidence through 2026.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eli Lilly emphasizes AI's impact on healthcare, enhancing drug discovery and diagnostics, potentially shifting defensive medical stocks to growth opportunities by 2026.
Why It Matters
Eli Lilly's emphasis on AI in healthcare signals potential growth in medical stocks, indicating a shift from defensive to growth-oriented investments, appealing for future profitability.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About MDT Stock
What is Medtronic plc's (MDT) stock forecast for 2026?
Based on our analysis of 34 Wall Street analysts, Medtronic plc (MDT) has a median price target of $112.00. The highest price target is $125.00 and the lowest is $97.20.
Is MDT stock a good investment in 2026?
According to current analyst ratings, MDT has 16 Buy ratings, 13 Hold ratings, and 0 Sell ratings. The stock is currently trading at $96.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDT stock?
Wall Street analysts predict MDT stock could reach $112.00 in the next 12 months. This represents a 15.5% increase from the current price of $96.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medtronic plc's business model?
Medtronic generates revenue by designing, manufacturing, and selling a diverse range of medical devices and therapies, focusing on areas such as cardiovascular treatment, diabetes management, and neurosurgery. The company's extensive product portfolio allows it to cater to various medical procedures, ensuring a steady demand for its innovative solutions.
What is the highest forecasted price for MDT Medtronic plc?
The highest price target for MDT is $125.00 from Joshua Jennings at Cowen & Co., which represents a 28.9% increase from the current price of $96.95.
What is the lowest forecasted price for MDT Medtronic plc?
The lowest price target for MDT is $97.20 from at , which represents a 0.3% increase from the current price of $96.95.
What is the overall MDT consensus from analysts for Medtronic plc?
The overall analyst consensus for MDT is bullish. Out of 34 Wall Street analysts, 16 rate it as Buy, 13 as Hold, and 0 as Sell, with a median price target of $112.00.
How accurate are MDT stock price projections?
Stock price projections, including those for Medtronic plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 3:13 AM UTC